← Back to all trials
Active Not Recruiting
NCT05607810
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 22
Sponsor: Adverum Biotechnologies, Inc.
Location: Adverum Clinical Site Beverly Hills California
Summary
This is a prospective, observational study designed to evaluate the long-term safety and tolerability of ADVM-022 in participants with diabetic macular edema (DME). Participants who previously participated in the INFINITY parent study and received a single unilateral intravitreal dose of ADVM-022 are eligible for enrollment upon completion of the end of study visit in the parent study.
Eligibility Criteria
Inclusion Criteria:
* Must have participated in the ADVM-022-04 \[INFINITY\] (parent) study and received ADVM-022
* Must provide signed informed consent
* Must be willing and able to comply with all study procedures
Exclusion Criteria:
\- None
Source: ClinicalTrials.gov (NCT05607810). StuddyBuddy aggregates publicly available trial information.
